PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $390,949 | -27.6% | 37,700 | 0.0% | 0.00% | – |
Q2 2023 | $539,864 | +177.0% | 37,700 | +38.1% | 0.00% | – |
Q1 2023 | $194,922 | -22.8% | 27,300 | +21.3% | 0.00% | – |
Q4 2022 | $252,450 | +44.3% | 22,500 | +42.4% | 0.00% | – |
Q3 2022 | $175,000 | +42.3% | 15,800 | +8.2% | 0.00% | – |
Q2 2022 | $123,000 | -22.6% | 14,600 | +24.8% | 0.00% | – |
Q1 2022 | $159,000 | -37.4% | 11,700 | -9.3% | 0.00% | – |
Q4 2021 | $254,000 | -28.0% | 12,900 | +17.3% | 0.00% | – |
Q3 2021 | $353,000 | -15.1% | 11,000 | -10.6% | 0.00% | – |
Q2 2021 | $416,000 | +5.6% | 12,300 | +17.1% | 0.00% | – |
Q1 2021 | $394,000 | +4.0% | 10,500 | -7.9% | 0.00% | – |
Q4 2020 | $379,000 | -14.6% | 11,400 | -5.8% | 0.00% | – |
Q3 2020 | $444,000 | -3.7% | 12,100 | -13.6% | 0.00% | – |
Q2 2020 | $461,000 | – | 14,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |